PDSB
PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.
PDSB
Market-moving news on PDS Biotechnology (NASDAQ: PDSB): filings, earnings, deals and other events, from REDFILED.
PDSB
PDS BIOTECHNOLOGY (PDSB) Refocuses on IL-12 Asset After Nant Capital Financing
Corporate deck filed with the SEC shows a 71.4% six-month response rate for PDS0301 in liver-metastatic colorectal cancer and a new board seat for Patrick Soon-Shiong.
PDSB
PDS (PDSB) BIOTECH Closes $11.3M of $22.3M PIPE Led by Soon-Shiong
PDS Biotech raised $11.3 million in an initial PIPE closing led by Nant Capital, added Patrick Soon-Shiong to its board and granted NantWorks an option on PDS0101.
PDSB
PDS BIOTECH Raises $11.3M in PIPE Led by Patrick Soon-Shiong
Nant Capital led an initial $11.3 million private placement in PDS Biotech, with up to $11 million more tied to a Phase 3 filing, and two Nant executives joining the board.